Alnylam Pharmaceuticals (ALNY) Change in Cash (2009 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Change in Cash came in at -$2.9 million in Q2 2026, down 103.14% YoY from $93.6 million in Q2 2025, and down 105.49% on a QoQ basis from $53.6 million in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Change in Cash (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 18 years of Change in Cash data on file, last reported at -$2.9 million in Q2 2026.
- Quarterly Change in Cash fell 103.14% year-over-year to -$2.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $593.6 million (up 310.33% YoY) and the FY2025 annual result came in at $690.2 million, up 348.83% from the prior year.
- Change in Cash eased to -$2.9 million in Q2 2026, from $53.6 million in the prior quarter.
- In the past five years, Change in Cash ranged from a high of $497.7 million in Q3 2022 to a low of -$285.9 million in Q1 2022.
- A 5-year average of $49.3 million and a median of $47.5 million in 2022 frame the typical range for Change in Cash.
- Annual changes were most pronounced in 2022 — Change in Cash slumped 144.27% — and 2024, when it soared 2084.58%.
- Tracing ALNY's Change in Cash over 5 years: stood at -$206.8 million in 2022, then fell by 6.52% to -$220.3 million in 2023, then surged by 39.25% to -$133.8 million in 2024, then soared by 224.03% to $166.0 million in 2025, then slumped by 101.77% to -$2.9 million in 2026.
- The last three Change in Cash figures came in at -$2.9 million (Q2 2026), $53.6 million (Q1 2026), and $166.0 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 427.25 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.97 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -2.94 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.42 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -170.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.94 Mn |
| Mar 31, 2026 | 53.61 Mn |
| Dec 31, 2025 | 166.01 Mn |
| Sep 30, 2025 | 376.94 Mn |
| Jun 30, 2025 | 93.61 Mn |
| Mar 31, 2025 | 53.60 Mn |
| Dec 31, 2024 | -133.85 Mn |
| Sep 30, 2024 | 131.31 Mn |
| Jun 30, 2024 | 286.47 Mn |
| Mar 31, 2024 | -130.17 Mn |
| Dec 31, 2023 | -220.33 Mn |
| Sep 30, 2023 | 375.23 Mn |
| Jun 30, 2023 | -14.44 Mn |
| Mar 31, 2023 | -194.15 Mn |
| Dec 31, 2022 | -206.83 Mn |
| Sep 30, 2022 | 497.65 Mn |
| Jun 30, 2022 | 41.48 Mn |
| Mar 31, 2022 | -285.89 Mn |
| Dec 31, 2021 | -274.31 Mn |
| Sep 30, 2021 | 348.39 Mn |